Offerings // Amneal Pharmaceuticals, Inc.

AMRX offering history

Every offering-related filing in Amneal Pharmaceuticals, Inc.’s recent SEC record — registrations (announced capacity) kept separate from pricing documents (executed sales). Reviewed 673 filings back to Nov 21, 2017.

Last executed offering

Aug 10, 2026

8-K — priced deal (shares or notes)

Last registration (announced)

Mar 2, 2022

S-3ASR — capacity, not a sale

Executed, last 12 months

424B pricings + 8-K 3.02 sales

Registered, last 12 months

S-1/S-3/F-series registrations

Date	Filing		What it means
Aug 10, 2026	8-K →	EXECUTED	Unregistered share sale disclosed (8-K item 3.02)
Apr 22, 2026	8-K →	EXECUTED	Unregistered share sale disclosed (8-K item 3.02)
Nov 14, 2023	EFFECT →	EFFECTIVE	SEC declared a registration effective — selling can begin
Nov 14, 2023	EFFECT →	EFFECTIVE	SEC declared a registration effective — selling can begin
Mar 24, 2023	EFFECT →	EFFECTIVE	SEC declared a registration effective — selling can begin
Mar 24, 2023	EFFECT →	EFFECTIVE	SEC declared a registration effective — selling can begin
Mar 2, 2022	S-3ASR →	REGISTERED	Automatic shelf registration — effective immediately (large filers)
Mar 2, 2022	S-3ASR →	REGISTERED	Automatic shelf registration — effective immediately (large filers)
Mar 1, 2019	S-3ASR →	REGISTERED	Automatic shelf registration — effective immediately (large filers)
Nov 13, 2018	424B3 →	UPDATE	Prospectus update — often a resale registration, not necessarily new capital
Sep 7, 2018	424B7 →	UPDATE	Resale prospectus — existing holders registering to sell
Aug 13, 2018	424B3 →	UPDATE	Prospectus update — often a resale registration, not necessarily new capital
Jul 12, 2018	424B3 →	UPDATE	Prospectus update — often a resale registration, not necessarily new capital
Jun 7, 2018	424B3 →	UPDATE	Prospectus update — often a resale registration, not necessarily new capital
May 11, 2018	424B3 →	UPDATE	Prospectus update — often a resale registration, not necessarily new capital
May 10, 2018	424B3 →	UPDATE	Prospectus update — often a resale registration, not necessarily new capital
May 9, 2018	S-1/A →	REGISTERED	S-1/A registration — capacity to sell shares, not a sale yet
May 9, 2018	EFFECT →	EFFECTIVE	SEC declared a registration effective — selling can begin
May 7, 2018	8-K →	EXECUTED	Unregistered share sale disclosed (8-K item 3.02)
May 7, 2018	RW →	WITHDRAWN	Registration withdrawn
May 7, 2018	S-1 →	REGISTERED	S-1 registration — capacity to sell shares, not a sale yet
Apr 13, 2018	S-1/A →	REGISTERED	S-1/A registration — capacity to sell shares, not a sale yet
Mar 7, 2018	S-1 →	REGISTERED	S-1 registration — capacity to sell shares, not a sale yet
Feb 12, 2018	424B3 →	UPDATE	Prospectus update — often a resale registration, not necessarily new capital
Feb 9, 2018	EFFECT →	EFFECTIVE	SEC declared a registration effective — selling can begin

AMRX offering-related filings from SEC EDGAR, newest first (capped at 40). Each links to the original document.

Two honest limits. (1) A 424B takedown can price shares or notes— EDGAR’s metadata doesn’t say which, so open the document: large investment-grade filers use these mostly for bond deals (no dilution), small-caps mostly for shares. (2) At-the-market (ATM) programs sell shares gradually and individual sales are not separately filed — the visible footprint is the enabling shelf and its 424B5; actual ATM share counts surface later in the 10-Q/10-K share count. Educational information from public filings, not investment advice.

Is a shelf active now? →Do they need money? →Red flags →Full AMRX workspace →

AMRX offering FAQ

When did AMRX last execute an offering?

Per SEC filings, Amneal Pharmaceuticals, Inc.'s most recent priced offering document is a 8-K filed 2026-08-10. Note a 424B takedown can price shares or notes (debt) — the linked document says which.

When did AMRX last announce or register an offering?

The most recent registration is a S-3ASR filed 2022-03-02. A registration is capacity to sell shares — not a sale.

Does an offering always mean dilution?

Registered direct offerings and shelf takedowns issue new shares and dilute existing holders. Resale registrations (424B3/B7) let existing holders sell and do not create new shares. Secondary sales by insiders also do not dilute. Each row here is labeled with what it is.